EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

An overview of global public and philanthropic investments into antibacterial therapeutics (2017–23)

Lloyd Czaplewski, Usha Lamichhane, Ralf Sudbrak, Alan Hennessy, Lesley A Ogilvie, Laura Jv Piddock

The Lancet Microbe · 2026

DOI: 10.1016/j.lanmic.2025.101288 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Lancet Microbe, 2026. Verfasst von Lloyd Czaplewski und 5 weiteren Autor:innen. Beteiligte Einrichtung: Chemical Biology Ventures, Abingdon, UK. Electronic address: Lloyd.czaplewski@chembioventures.com. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Investments, Drug Development. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Wellcome, Bill and Melinda Gates Foundation, GlaxoSmithKline Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibacterial research and development (R&D) increasingly relies on public and philanthropic investments over private investments and on academia and small businesses over large pharmaceutical companies. To complement scientific reviews of the antibacterial pipeline, we examined global public and philanthropic funding for R&D of antibacterial therapeutics from 2017 to 2023 using data obtained from the Global AMR R&D Hub's Dynamic Dashboard. Projects were analysed considering funders and recipients, geographical location, R&D stage, mechanism of action, antibacterial class, clinical novelty, spectrum of activity, and alignment with the WHO bacterial priority pathogen list 2024. A total of US$2·51 billion was invested in antibacterial R&D by 130 funders, with a marked concentration among a small number of major sources. Funding peaked at $445 million in 2020 but declined by 18% to $363 million in 2023. Universities received the most awards, yet more than half of the total funding volume went to industry recipients. Investment broadly followed the WHO bacterial priority pathogens list, with Mycobacterium tuberculosis accounting for a fifth of the total. While the funding for clinical development remained stable, that for discovery and preclinical research declined. In this environment, public-private partnerships, such as Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator and the Global Antibiotic Research and Development Partnership, are crucial for attracting, channelling, and targeting funding; however, these partnerships alone will be insufficient. Enhanced strategic alignment in funding priorities and continued public and private investment will be essential for ensuring the discovery and development of effective new antibacterials meeting priority public health needs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsInvestmentsDrug DevelopmentHumansDrug IndustryDrug DiscoveryGlobal Health

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Chemical Biology Ventures, Abingdon, UK. Electronic address: Lloyd.czaplewski@chembioventures.com.
  • Global Antimicrobial Resistance Research and Development Hub, Berlin, Germany.
  • Global Antibiotic Research & Development Partnership (GARDP), Geneva, Switzerland.

Förderung

  • Wellcome
  • Bill and Melinda Gates Foundation
  • GlaxoSmithKline Japan
  • Research and Development
  • South African Medical Research Council
  • Canton de Genève
  • World Health Organization
  • Federal Ministry of Education and Research Bonn Office

Zitieren

APA

Czaplewski, L., Lamichhane, U., Sudbrak, R., Hennessy, A., Ogilvie, L. A., & Piddock, L. J. (2026). An overview of global public and philanthropic investments into antibacterial therapeutics (2017–23). The Lancet Microbe. https://doi.org/10.1016/j.lanmic.2025.101288

Vancouver

Czaplewski L, Lamichhane U, Sudbrak R, Hennessy A, Ogilvie LA, Piddock LJ. An overview of global public and philanthropic investments into antibacterial therapeutics (2017–23). The Lancet Microbe. 2026. doi:10.1016/j.lanmic.2025.101288

BibTeX
@article{Czaplewski2026,
  author = {Czaplewski, Lloyd and Lamichhane, Usha and Sudbrak, Ralf and Hennessy, Alan and Ogilvie, Lesley A and Piddock, Laura Jv},
  title = {An overview of global public and philanthropic investments into antibacterial therapeutics (2017–23)},
  journal = {The Lancet Microbe},
  year = {2026},
  doi = {10.1016/j.lanmic.2025.101288}
}
Kostenlos starten →